One study analyzed clinical trial and real-world data to evaluate the clinical utility of PD-L1 and tumor mutational burden (TMB) as predictive biomarkers for PD-1 and PD-L1 checkpoint inhibitor response. Here, CD274 is linked to neoplasm.